Drug-induced kidney injury in Chinese critically ill pediatric patients

Biwen Hu1, Ling Ye1, Tong Li1

  • 1Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

Frontiers in Pharmacology
|October 13, 2022
PubMed

Insights

Drug-induced acute kidney injury (DIKI) in critically ill children is often linked to specific medications. Furosemide, midazolam, albumin, fentanyl, glycyrrhizin, vancomycin, and milrinone were identified as high-risk drugs.

Area of Science:

  • Pediatric Nephrology
  • Clinical Pharmacology
  • Critical Care Medicine

Background:

  • Drug-induced acute kidney injury (DIKI) is a recognized adverse drug reaction, yet its prevalence and specific drug associations in pediatric populations remain under-investigated.
  • The Pediatric Intensive Care database (PIC) provides a valuable resource for studying DIKI in critically ill children.

Purpose of the Study:

  • To investigate the incidence and identify key drugs associated with DIKI in Chinese pediatric patients admitted to the intensive care unit.
  • To assess the relationship between specific drug exposures and the occurrence of DIKI using established causality assessment scales.

Main Methods:

  • Patients with acute kidney injury (AKI) were identified using KDIGO criteria from the PIC database.
  • The Naranjo scale was employed to assess the causality of DIKI for suspected drugs.
  • Propensity score matching (PSM) was utilized to control for confounders including age, gender, hospital stay duration, and primary diagnosis.
  • Unconditional logistic regression analysis was performed to determine significant associations between drug exposure and DIKI.

Main Results:

  • A total of 81 pediatric patients with DIKI were identified, with 238 drugs administered 1,863 times.
  • Seven drugs were significantly associated with DIKI after analysis: furosemide injection (p=0.001), midazolam injection (p=0.001), 20% albumin prepared from human plasma injection (p=0.004), fentanyl citrate injection (p=0.001), compound glycyrrhizin injection (p=0.026), vancomycin hydrochloride for intravenous (p=0.010), and milrinone lactate injection (p=0.009).

Conclusions:

  • Critically ill pediatric patients exhibit a higher risk of developing DIKI when exposed to specific medications.
  • Furosemide, midazolam, albumin, fentanyl, glycyrrhizin, vancomycin, and milrinone are identified as key drugs requiring careful monitoring for potential nephrotoxicity in this vulnerable population.

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
53
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
40
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
59
Acute Kidney Injury VI: Nursing Management01:22

Acute Kidney Injury VI: Nursing Management

Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
48
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
56
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
68